Methods for treating hair loss disorders
US-10265258-B2 · Apr 23, 2019 · US
Methods for treating hair loss disorders
US2020237635A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2020237635-A1 |
| Application number | US-202016796608-A |
| Country | US |
| Kind code | A1 |
| Filing date | Feb 20, 2020 |
| Priority date | Nov 2, 2010 |
| Publication date | Jul 30, 2020 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
First claim
Opening claim text (preview).
1 - 28 . (canceled) 29 . A method of treating a hair-loss disorder in a human in need thereof comprising orally administering to the human an effective amount of a janus kinase (JAK) inhibitor having the following structure: in a pharmaceutical composition, wherein the hair-loss disorder is alopecia areata. 30 . The method of claim 29 , wherein the alopecia areata is alopecia totalis. 31 . The method of claim 29 , wherein the alopecia areata is alopecia universalis. 32 . The method of claim 29 , wherein the pharmaceutical composition is selected from a capsule, a tablet, a pill, and a troche. 33 . A method of treating a hair-loss disorder in a human in need thereof comprising orally administering once daily or twice daily to the human an effective amount of a janus kinase (JAK) inhibitor having the following structure: in a pharmaceutical composition, wherein the hair-loss disorder is alopecia areata. 34 . The method of claim 33 , wherein the alopecia areata is alopecia totalis. 35 . The method of claim 33 , wherein the alopecia areata is alopecia universalis. 36 . The method of claim 33 , wherein the pharmaceutical composition is selected from a capsule, a tablet, a pill, and a troche. 37 . The method of claim 33 , wherein the pharmaceutical composition is orally administered once daily. 38 . The method of claim 33 , wherein the pharmaceutical composition is orally administered twice daily.
Assignees
Inventors
Classifications
- A61K31/713Primary
Double-stranded nucleic acids or oligonucleotides · CPC title
- A61K8/4953Primary
containing pyrimidine ring derivatives, e.g. minoxidil · CPC title
Amines · CPC title
Proteins; Peptides; Derivatives or degradation products thereof · CPC title
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2020237635A1 cover?
- The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
- Who is the assignee on this patent?
- Univ Columbia
- What technology area does this patent fall under?
- Primary CPC classification A61K31/713. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Jul 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).